Better Therapeutics, a prescription digital therapeutic startup, has entered a rebate agreement with a major pharmacy benefit manager (PBM) regarding its AspyreRx product.
Under this agreement, the PBM's plan participants gain access to add AspyreRx to their formularies with rebate eligibility. AspyreRx, approved by the FDA in July 2023 to treat adults with type 2 diabetes, is designed to change neural pathways, causing lasting behavioral change and addressing the underlying causes of the disease. Better Therapeutics is actively promoting its PDTs to health plans, PBMs, and Group Purchasing Organizations to increase accessibility and coverage.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.